SIADH
11
1
2
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
9.1%
1 terminated out of 11 trials
80.0%
-6.6% vs benchmark
9%
1 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (11)
Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia
Urea Therapy for Hyponatremia in Subarachnoid Hemorrhage
Asymptomatic Bacteriuria, Hyponatremia and Geri-atric Syndrome
Low-dose Tolvaptan for Inpatient Hyponatraemia.
Changes in Serum Creatinine Levels Can Help Distinguish Hypovolemic From Euvolemic Hyponatremia
Hyponatraemia and Mortality in Schizophrenic and Bipolar Patients: Protocol for a Bayesian Causal Inference Study
Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study
Fractional Urate Excretion in Nonedematous Hyponatremia
Tolvaptan for Patients With Acute Neurological Injuries
Post-Authorisation Safety Study of Samsca (Tolvaptan) Used in Routine Medical Practice
The Clinical and Laboratory Characteristics of Recurrent Drug- Related Hyponatremia